Gonadorelin side effects and risks

Reported side effects

• Pump-site skin allergy: 7/20 (35%) in one male pump cohort; not a bolus test rate., moderate (source)
• Pain, swelling or itching: UK bolus label: 0.1% to <1%., mild (source)
• Headache, dizziness or nausea: UK bolus label: 0.01% to <0.1%., mild (source)
• Allergy or airway spasm: UK label classifies hypersensitivity and bronchospasm as rare., serious (source)
• IV-line infection or vein inflammation: Historical IV line complications averaged 7%; includes more than infection., serious (source)
• Multiple pregnancy or ovarian over-response: 12% multiple pregnancy in the 1990 program; 1.6% twins in the 2022 cohort., serious (source)
• Pituitary bleeding in a tumor: unknown, serious. Sudden severe headache or vision loss needs emergency assessment. (source)

Stop and get help if

• Sudden severe headache, vision change, vomiting or collapse: Seek emergency care for possible pituitary bleeding.
• Throat swelling, wheeze or faintness after injection: Seek emergency care for possible severe allergy.
• Fever, spreading redness or chills with a pump or IV line: Get urgent assessment for possible infection.
• Severe pelvic pain, rapid weight gain or breathlessness: Get urgent assessment for ovarian over-response.

Who should avoid it

• pregnant: UK product information says not to administer during pregnancy.
• breastfeeding: UK product information says not to administer while nursing.
• tryingToConceive: Specialist fertility use requires diagnosis and monitoring.
• under18: Pediatric research is not an adult self-use regimen.
• hormoneSensitiveCancer: Precaution: gonadorelin raises sex hormones; breast or prostate cancer requires an oncology plan.
• other: GnRH can trigger bleeding into a pituitary adenoma.
• other: Prior allergy to gonadorelin or its excipients can recur.
• other: Primary gonadal failure or poor pituitary reserve can limit response; diagnose the cause first.
• testedAthlete: Prohibited at all times in male athletes under WADA S2.2.1.
• other: Stop for signs of severe allergy or a serious pump-site infection.

Interactions

• Testosterone and other sex hormones: These can alter LH/FSH response. Intermittent gonadorelin has not been shown to preserve fertility during TRT.
• Glucocorticoids: Can affect pituitary gonadotropin secretion and diagnostic interpretation.
• Prolactin-raising drugs: Dopamine antagonists can blunt the GnRH response through higher prolactin.
• Spironolactone, methyldopa and digoxin: Can alter measured gonadotropins and test interpretation.
• Other GnRH medicines: Other drugs acting on the same axis can suppress or change response; they are not dose substitutes.
• Clomiphene with ovulation induction: A historical hyperstimulation case also used clomiphene; combination monitoring matters.

Product quality risks

• An FDA recall included compounded gonadorelin because of sterility concerns.
• A June 2026 FDA warning identified an unapproved gonadorelin product. A research label does not establish approval.
• No representative assay survey of online gonadorelin vials was found.